September 2023 FDA Recall Triamcinolone Acetonide by Eugia Us Llc
D-0041-2024 - Presence of Particulate Matter

This Class II drug recall was voluntarily initiated by Eugia Us Llc on September 28, 2023 for the product Triamcinolone Acetonide. The FDA reported the reason for recall as presence of particulate matter. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-0041-2024

Reason for Recall
Presence of Particulate Matter: A product complaint of a piece of glass was identified in a vial. The piece of glass appears to be roughly 1 cm x 0.5 cm inside the vial.
Initiated
09-28-2023
Reported
10-11-2023
Quantity
1,626 vials

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Nationwide in the USA
Triamcinolone Acetonide Injectable Suspension, USP, 400 mg per 10 mL (40mg/mL), 10 mL Multiple Dose Vial, Rx Only, For Intramuscular or Intra-articular use only, Shake Well, Not for IV/ID, intraocular, epidural, or intrathecal use, Mfd. in India for Auromedics Pharma LLC., E Windsor, NJ, 08520, NDC 55150-385-01.

Batch or Lot Expiration Information

Lot# : 3TC22010, Exp 11/30/2024